DE69909041D1 - Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie - Google Patents

Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie

Info

Publication number
DE69909041D1
DE69909041D1 DE69909041T DE69909041T DE69909041D1 DE 69909041 D1 DE69909041 D1 DE 69909041D1 DE 69909041 T DE69909041 T DE 69909041T DE 69909041 T DE69909041 T DE 69909041T DE 69909041 D1 DE69909041 D1 DE 69909041D1
Authority
DE
Germany
Prior art keywords
magnesium
gene
increase
gene therapy
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69909041T
Other languages
English (en)
Other versions
DE69909041T2 (de
Inventor
Serge Braun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Association Francaise Contre les Myopathies
Original Assignee
Transgene SA
Association Francaise Contre les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA, Association Francaise Contre les Myopathies filed Critical Transgene SA
Application granted granted Critical
Publication of DE69909041D1 publication Critical patent/DE69909041D1/de
Publication of DE69909041T2 publication Critical patent/DE69909041T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
DE69909041T 1998-09-30 1999-09-30 Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie Expired - Lifetime DE69909041T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98402424A EP0998945A1 (de) 1998-09-30 1998-09-30 Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
EP98402424 1998-09-30

Publications (2)

Publication Number Publication Date
DE69909041D1 true DE69909041D1 (de) 2003-07-31
DE69909041T2 DE69909041T2 (de) 2004-04-01

Family

ID=8235506

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69909041T Expired - Lifetime DE69909041T2 (de) 1998-09-30 1999-09-30 Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie

Country Status (10)

Country Link
US (2) US20020019357A1 (de)
EP (2) EP0998945A1 (de)
JP (1) JP5172054B2 (de)
AT (1) ATE243531T1 (de)
AU (1) AU767294B2 (de)
CA (1) CA2284399C (de)
DE (1) DE69909041T2 (de)
DK (1) DK1004320T3 (de)
ES (1) ES2201611T3 (de)
PT (1) PT1004320E (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001080897A2 (en) * 2000-04-21 2001-11-01 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
EP1249244A1 (de) 2001-04-13 2002-10-16 Universiteit Gent Therapeutische Zusammensetzungen zur Behandlung einer g-actin / f-actin-gleichgewicht vermittelten Erkrankung, z.b. einer respiratorischen Erkrankung
WO2003000908A1 (en) * 2001-06-21 2003-01-03 Ecole Polytechnique Federale De Lausanne A method for introducing a nucleic acid into a eukaryotic cell
EP1270733A1 (de) * 2001-06-21 2003-01-02 Ecole Polytechnique Federale De Lausanne Verfahren zum Einbringen von Nukleinsäure in eukaryotische Zellen
WO2004075924A1 (ja) * 2003-01-17 2004-09-10 Japan Genome Solutions, Inc. 遺伝子導入促進剤およびそれを含む遺伝子導入用組成物
EP1925626A1 (de) 2003-07-21 2008-05-28 Transgene S.A. Neue multifunktionelle Cytokine
DE102005007744A1 (de) * 2004-06-24 2006-01-19 Shf Communication Technologies Ag Planetengetriebe zur Kombination unterschiedlicher Energiequellen
GB0817393D0 (en) * 2008-09-23 2008-10-29 Givaudan Sa Flavour
EP2405959A4 (de) * 2009-03-13 2013-10-16 Univ Tufts Verfahren, vorrichtungen und kits zur einführung von genetischem material in lebende zellen
CN109134640A (zh) 2012-10-23 2019-01-04 爱默蕾大学 Gm-csf和il-4轭合物、组合物以及与其相关的方法
WO2019222666A1 (en) * 2018-05-17 2019-11-21 University Of Florida Research Foundation, Incorporated Methods and compositions for using metal elements in aav gene therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60188069A (ja) * 1984-03-08 1985-09-25 Nakano Vinegar Co Ltd 酢酸菌の環状ｄνａ導入法
US4798789A (en) * 1984-10-05 1989-01-17 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
JPH08308573A (ja) * 1995-05-19 1996-11-26 Ube Ind Ltd 細胞への遺伝子導入方法及びそれに用いられるウィルス感染培地
WO1997012992A2 (en) * 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
US5994316A (en) * 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5830698A (en) * 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
AU752658B2 (en) * 1998-05-06 2002-09-26 Association Francaise Contre Les Myopathies Use of a nuclease inhibitor or interleukin-10 (IL-10) for the preparation of a therapeutic composition for improving transfection of a polynucleotide into a cell and compositions useful in gene therapy

Also Published As

Publication number Publication date
EP0998945A1 (de) 2000-05-10
DK1004320T3 (da) 2003-09-15
JP2000143549A (ja) 2000-05-23
US20020019357A1 (en) 2002-02-14
US20020156045A1 (en) 2002-10-24
DE69909041T2 (de) 2004-04-01
JP5172054B2 (ja) 2013-03-27
AU5139799A (en) 2000-04-06
ATE243531T1 (de) 2003-07-15
EP1004320B1 (de) 2003-06-25
ES2201611T3 (es) 2004-03-16
PT1004320E (pt) 2003-10-31
US6881724B2 (en) 2005-04-19
CA2284399A1 (en) 2000-03-30
AU767294B2 (en) 2003-11-06
CA2284399C (en) 2011-01-18
EP1004320A1 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
DE69535576D1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
ATE200226T1 (de) Zusammensetzungen die verwendbar sind zur verabreichung von therapeutisch wirksamer polynukleotiden in eine zielzelle und ihre verwendung in gentherapie
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
ZA95137B (en) Composition containing nucleic acids preparation and use
IL160052A0 (en) Diagnostic and pharmaceutical compositions containing microorganisms or cells including a detectable protein
DE69909041D1 (de) Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
DE69325256D1 (de) Insizierbare lecithin gel
CA2346119A1 (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
MX9700270A (es) Composicion que contiene acidos nucleicos, preparacion y utilizacion.
AU687112B2 (en) Methods for increasing extracellular adenosine and for stabilization mast cells
ATE197719T1 (de) Verwendung von mesothelialen zellen in der gentherapie
JPS51106114A (de)
EP2292771A3 (de) Sense mRNA Therapie
EP1153924A3 (de) Substutuierte 1,3-Oxathiolane mit antiviralen Eigenschaften
IL165350A0 (en) Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
PT80300A (de) Herstellung von polypeptiden mit human-gammainterferonaktivitat
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
EP0848948A4 (de) Lang wirksames mittel zur rektalen verabreichung
DE3586281D1 (de) Antisaeurezusammensetzung.
ATE258933T1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
ATE184788T1 (de) Idebenone-haltige zusammensetzungen zur behandlung von m. alzheimer
ZA883744B (en) Promotion of healing of meniscal tissue
DE3879575D1 (de) Alpha-carotin zur wachstumshemmung von krebszellen.
AU2699195A (en) Biotin compounds for targetting tumors and sites of infection

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES, E, FR